Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 9/20 | 0.67 |
| ▸ | CDK2 | P24941 | 7/20 | 0.66 |
| ▸ | SRC | P12931 | 2/20 | 0.66 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.66 |
| ▸ | CDK1 | P06493 | 8/20 | 0.60 |
| ▸ | CCNT1 | O60563 | 5/20 | 0.60 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.60 |
| ▸ | CDK9 | P50750 | 5/20 | 0.60 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.60 |
| ▸ | CDK7 | P50613 | 4/20 | 0.60 |
| ▸ | CCNH | P51946 | 4/20 | 0.60 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.60 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.59 |
| ▸ | MTOR | P42345 | 4/20 | 0.57 |
| ▸ | SMG1 | Q96Q15 | 4/20 | 0.57 |
| ▸ | IKBKB | O14920 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13924492 | 0.86 | SYK (0.68) | SYKCDK2SRCZAP70CDK1 | |
| SCHEMBL13924445 | 0.81 | SYK (0.75) | SYKCDK2SRCZAP70 | |
| SCHEMBL7524252 | 0.80 | CDK1 (0.69) | SYKCDK2SRCCDK1CCNT1 | |
| SCHEMBL7464681 | 0.80 | CDK1 (0.61) | SYKCDK2CDK1CCNT1CCNB1 | |
| SCHEMBL13924480 | 0.80 | SYK (0.69) | SYKCDK2SRCZAP70CDK9 | |
| SCHEMBL13924456 | 0.80 | SYK (0.73) | SYKCDK2SRCZAP70 | |
| SCHEMBL13924470 | 0.80 | SYK (0.73) | SYKCDK2SRCZAP70 | |
| SCHEMBL13924459 | 0.80 | SYK (0.73) | SYKCDK2SRCZAP70 | |
| SCHEMBL13924432 | 0.80 | SYK (1.00) | SYKCDK2SRCZAP70CDK1 | |
| SCHEMBL13924468 | 0.80 | SYK (0.73) | SYKCDK2SRCZAP70 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048282-A1 | PYRIMIDINE SULFONAMIDE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-19 | — | — | US | claimed |
| US-20090048282-A1 | PYRIMIDINE SULFONAMIDE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048282-A1 | PYRIMIDINE SULFONAMIDE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WNT1, CTNNB1, WNT3A | SYK 3093/4885CDK2 116/4885SRC 1155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.